Publicacións en colaboración con investigadores/as de University of Tampere (15)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  3. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 184, pp. 168-177

2023

  1. A plea for systematic literature analysis and conclusive study design, comment on: "Systematic review of magnetic resonance imaging for diagnosis of Meniere disease"

    Journal of vestibular research : equilibrium & orientation, Vol. 33, Núm. 2, pp. 151-157

  2. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

    Annals of Oncology, Vol. 34, Núm. 8, pp. 681-692

2022

  1. COVID-19 pandemic impact on cytopathology practice in the post-lockdown period: An international, multicenter study

    Cancer Cytopathology, Vol. 130, Núm. 5, pp. 344-351

2021

  1. Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial

    Journal of the National Cancer Institute, Vol. 113, Núm. 7, pp. 917-923

2020

  1. European Association for the Study of Obesity Position Statement on the Global COVID-19 Pandemic

    Obesity Facts, Vol. 13, Núm. 2, pp. 292-296

  2. Global impact of the COVID-19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries

    Cancer Cytopathology, Vol. 128, Núm. 12, pp. 885-894

  3. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies

    Annals of Oncology, Vol. 31, Núm. 9, pp. 1186-1197

2019

  1. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2416-2428

2017

  1. Balancing Upstream and Downstream Measures to Tackle the Obesity Epidemic: A Position Statement from the European Association for the Study of Obesity

    Obesity Facts, Vol. 10, Núm. 1, pp. 61-63

2016

  1. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 27, Núm. 1, pp. 16-41

2014

  1. Adipocyte morphology and implications for metabolic derangements in acquired obesity

    International Journal of Obesity, Vol. 38, Núm. 11, pp. 1423-1431

  2. Characterising metabolically healthy obesity in weight-discordant monozygotic twins

    Diabetologia, Vol. 57, Núm. 1, pp. 167-176